Blue Biotech ????: Latest Trends
"In one drop of water are found all the secrets of all the oceans." By Kahlil Gibran
Blue Economy ?? and Bio
According to the World Bank, the blue economy is the
"sustainable use of ocean resources for economic growth, improved livelihoods and jobs while preserving the health of the ocean ecosystem."
European Commission defines it as
"All economic activities related to oceans, seas and coasts.”
The 10 Key Blue Economy sectors are:
Blue biotechnology is the application of science and technology
to aquatic organisms,
using biological and chemical methods to produce knowledge, goods, products and services.
Blue biotechnology is quite concentrated around four countries in the EU with particularly strong focus on scientific research and innovation: France, Italy, Spain and Germany. Over the past 20 years, the vast majority of European deals in the Blue Biotechnology sector occurred within the EU, with almost 78% of the total number of deals. 22% of the deals took place in the rest of Europe, mostly in the UK and to some extent Switzerland, both of which also have strong scientific traditions. Globally, the blue biotechnology market is expected to reach about €5 billion by 2029, at an annual growth rate of about 7% since 2021. The US held 87.29% share of North America for the blue biotechnology market in 2023. Regarding Blue Economy, Portugal and Mexico also show a strong focus on the blue economy with the Nordics (Iceland and Norway) being the countries with the most share of funding going into the Blue Economy.
According to dealroom, VC funding in Bluetech biotechnology peaked at almost $300M in 2022, then dropped 1/3 in 2023. Almost $900M have been invested since 2016.
Source:
Blue TechBio Companies
?? New Atlantis Labs, marine metagenomics
NewAtlantis (US)—dedicated to marine biodiversity and marine metagenomics for saving our oceans and preserving marine biodiversity—is about to quantify marine biodiversity ?? ?? with open meta omics to power sustainable and scalable ocean regeneration. At New Atlantis they believe that the phylogenetic diversity of the largely un-sequenced marine microbes and planktonic communities could provide a lot of novel potential secondary metabolites that might be of commercial interest. And with a partnership with Bacalhau—a platform for faster, cost efficient and more secure distributed computation, enabling users to run arbitrary Docker containers and WebAssembly images as tasks—they want to study the genome of the marine micro-organisms sampled directly from the ocean environment, using new high-throughput DNA sequencing technology and bioinformatics tools.
But there is more. Gordon Gould—the co-founder and co-CEO of New Atlantis—and his team don’t just want to protect the Marine Protected Areas (MPAs), the national parks of the oceans around the globe. They want also to empower the communities around the MPAs—that most of the times lack the resources to adequately protect life in their waters due to reliance on precarious government funding and traditional philanthropy—by providing MPAs with a viable business model that generates revenues based on MPA conservation efforts and outcomes achieved in their waters, by creating an open marine metagenomics biodiversity analytics platform from which ecosystem health can be evaluated in order to issue blue carbon and biodiversity credits as a revenue source for MPAs. Courtney Nichols Gould, Gordon’s wife, is the co-founder and co-CEO of New Atlantis Labs.
But what do you get when you blend the blue economy with biology and data science? You actually get a time travel back to our origins that gives you the possibility to study biological pathways, proteins and genes (of known and unknown metabolites) in different time points throughout evolution, enabling in the end the pharma sector and the tech sector to build more efficient models for drug discovery.
?? Holloid GmbH, digital holographic microscopy Holloid
Holloid (2020, Austria) provides high-speed 3D imaging and optical characterization monitoring using AI, digital holographic microscopy and patented software solutions to detect, identify and sort colloids, such as dispersed particles, cells and microorganisms. They provide easily customizable solutions for various industries:
领英推荐
?? Sirenas LLC, computational metabolomics Sirenas
Sirenas (2012, US) has sustainably and ethically built one of the largest and most unique collections of marine organisms and plants from diverse ecosystems and geographies (from the deep sea to coral reefs and estuaries).?These samples go through cutting edge and proprietary chemical extraction and analytics, and tested each one in over 70 in-vitro biological assays relevant to human health. The result is the largest repository of information connecting the uncharted chemistry of marine organisms to applications in human health.? Our insights reveal both extracts and single compounds that modulate inflammation, pathways in cancer, infectious disease and microbiome dynamics. Founder and CEO is Eduardo Esquenazi (Is a Cancer Breakthrough Living at the Bottom of the Sea?).
Their approach, dubbed ATLANTIS?, unleashes cutting-edge computational algorithms on large, proprietary metabolomic and bioassay datasets to rapidly uncover key chemical and biological insights for the small molecules present in complex samples from extremely biodiverse environments. The end result: the ability to mine a vastly untapped chemical language for new chemical scaffolds effective across a broad array of high value targets and disease models (Sirenas Receives Research Grant Totaling $1.68 M To Accelerate Its Drug Discovery Technology, ATLANTIS?).
On February 12, 2018, Sirenas announced that it has entered into a multi-target research collaboration agreement with Bristol-Myers Squibb to deploy Sirenas' drug discovery platform against certain undisclosed challenging therapeutic targets to identify potential drug candidates.? The research collaboration leverages Sirenas' expertise in applying ATLANTIS?, its data mining technology, to identify such potential drug candidates derived from Sirenas' proprietary chemical library isolated from global microbiome collections (Sirenas Enters Into Multi-Target Collaboration With Bristol-Myers Squibb).?
On Dec. 13, 2022, Sirenas and Hume Supernatural, Inc. (“Hume”), a leading personal care product company, announced that the companies have entered into a collaboration to bring new natural ingredients from diverse marine and terrestrial sources into the personal care space (Sirenas and Hume Supernatural Enter Into Strategic Collaboration to Create Science-Backed Personal Care Products).
Right now they have 5 programs in development (alongside their biotech partner, Galileo Biosystems): GB 499,408 (inflammation, IND enabling), SMD-5053 (malaria, preclinical), SMD-3218 (lupus, preclinical) and SMD-5004 and SMD-3265 (oncology, discovery).
?? Basecamp Research, AI-based biological design for genomes and proteins Basecamp Research
Basecamp Research (2019, UK) is a biotechnology company that partners with R&D?teams to develop proteins that meet their most challenging requirements in applications as broad as food, pharma and bioremediation. Having sampled from most extreme and extraordinary biomes on the planet, their knowledge graph of natural biodiversity is the most comprehensive and diverse in existence. This data advantage allows us to rapidly develop AI that outperforms state-of-the art. The company was founded by Oliver Vince and Glen Gowers. On March 12, 2024, Basecamp Research announced the launch of BaseFold, its new deep learning model?that predicts 3D structures of large, complex proteins?more accurately than?other AI-powered tools, including the industry gold standard, AlphaFold2 (IMPROVING ALPHAFOLD2 PERFORMANCE WITH A GLOBAL METAGENOMIC & BIOLOGICAL DATA SUPPLY CHAIN).
On June 18, 2024, Basecamp Research partnered with the Ferruz Laboratory at the Institute of Molecular Biology of Barcelona to unveil ZymCTRL ("enzyme control"). Modeled after large language models (LLMs) like ChatGPT, ZymCTRL allows users to generate new enzyme sequences simply by inputting an enzyme identification code, specifying the desired activity (Basecamp Research and Ferruz Laboratory Announce ZymCTRL: A Revolutionary AI Tool for Enzyme Design).
Basecamp Research has now raised a total of $30M.
Blue Economy Funds ?? for Blue TechBio
Funds
Mutual funds
Moreover, this is a list of examples of mutual funds with a focus on the Blue Economy are:
Exchange-traded funds (ETF)
In addition, exchange-traded funds (ETF) with a Blue Economy focus have also emerged. Three ETFs have been identified:
Until next time ??
Researcher| Gut microbiome! Talks about #Gut-Brain #microbiota, #Nutrients, #Cancer * Magic Microbiome: Personalized Medicine Starts in Your Gut. * Happy Colon, Balanced Life Starts Here!
6 个月Thanks for sharing dear Marina T Alamanou, PhD ????????
Co-Founder of Altrosyn and DIrector at CDTECH | Inventor | Manufacturer
6 个月The convergence of AI and biotech is poised to revolutionize healthcare, enabling personalized medicine and accelerating drug discovery. Just look at AlphaFold's groundbreaking protein structure predictions it's a testament to AI's potential in this field. Given your focus on metaphysical cells, how might AI help us understand the complex interplay between consciousness and biology?